nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—melanoma	0.548	0.748	CbGaD
Pseudoephedrine—TNF—melanoma	0.185	0.252	CbGaD
Pseudoephedrine—NFATC1—hair follicle—melanoma	0.0066	0.207	CbGeAlD
Pseudoephedrine—IL2—blood vessel—melanoma	0.00566	0.177	CbGeAlD
Pseudoephedrine—IL2—neck—melanoma	0.00405	0.127	CbGeAlD
Pseudoephedrine—IL2—skin of body—melanoma	0.00262	0.0821	CbGeAlD
Pseudoephedrine—NFATC1—head—melanoma	0.00187	0.0585	CbGeAlD
Pseudoephedrine—IL2—head—melanoma	0.00171	0.0535	CbGeAlD
Pseudoephedrine—NFATC1—lymph node—melanoma	0.00131	0.041	CbGeAlD
Pseudoephedrine—TNF—lymph node—melanoma	0.00125	0.0391	CbGeAlD
Pseudoephedrine—IL2—lymph node—melanoma	0.0012	0.0375	CbGeAlD
Pseudoephedrine—MAOA—neck—melanoma	0.000795	0.0249	CbGeAlD
Pseudoephedrine—Cerebral haemorrhage—Carmustine—melanoma	0.000759	0.0484	CcSEcCtD
Pseudoephedrine—Cerebral haemorrhage—Temozolomide—melanoma	0.000734	0.0467	CcSEcCtD
Pseudoephedrine—Paranoia—Carmustine—melanoma	0.000617	0.0393	CcSEcCtD
Pseudoephedrine—MAOA—retina—melanoma	0.000586	0.0184	CbGeAlD
Pseudoephedrine—MAOA—mammalian vulva—melanoma	0.000469	0.0147	CbGeAlD
Pseudoephedrine—SLC6A3—head—melanoma	0.000452	0.0141	CbGeAlD
Pseudoephedrine—ADRB1—head—melanoma	0.000429	0.0134	CbGeAlD
Pseudoephedrine—SLC6A4—head—melanoma	0.000414	0.013	CbGeAlD
Pseudoephedrine—SLC6A2—head—melanoma	0.000364	0.0114	CbGeAlD
Pseudoephedrine—ADRA2A—mammalian vulva—melanoma	0.00036	0.0113	CbGeAlD
Pseudoephedrine—ADRA1A—head—melanoma	0.000339	0.0106	CbGeAlD
Pseudoephedrine—MAOA—head—melanoma	0.000336	0.0105	CbGeAlD
Pseudoephedrine—Blood pressure increased—Docetaxel—melanoma	0.00027	0.0172	CcSEcCtD
Pseudoephedrine—ADRA2A—head—melanoma	0.000258	0.00807	CbGeAlD
Pseudoephedrine—SLC6A2—lymph node—melanoma	0.000255	0.00799	CbGeAlD
Pseudoephedrine—Decreased appetite—Vemurafenib—melanoma	0.000246	0.0157	CcSEcCtD
Pseudoephedrine—Lightheadedness—Docetaxel—melanoma	0.000242	0.0154	CcSEcCtD
Pseudoephedrine—Dysuria—Temozolomide—melanoma	0.000238	0.0152	CcSEcCtD
Pseudoephedrine—MAOA—lymph node—melanoma	0.000235	0.00736	CbGeAlD
Pseudoephedrine—Body temperature increased—Vemurafenib—melanoma	0.000224	0.0143	CcSEcCtD
Pseudoephedrine—Hallucination—Carmustine—melanoma	0.00021	0.0134	CcSEcCtD
Pseudoephedrine—Asthenia—Vemurafenib—melanoma	0.000203	0.013	CcSEcCtD
Pseudoephedrine—Hallucination—Temozolomide—melanoma	0.000203	0.0129	CcSEcCtD
Pseudoephedrine—CYP2D6—head—melanoma	0.0002	0.00625	CbGeAlD
Pseudoephedrine—Arrhythmia—Carmustine—melanoma	0.000189	0.012	CcSEcCtD
Pseudoephedrine—Dizziness—Vemurafenib—melanoma	0.000187	0.0119	CcSEcCtD
Pseudoephedrine—ADRA2A—lymph node—melanoma	0.00018	0.00565	CbGeAlD
Pseudoephedrine—Vomiting—Vemurafenib—melanoma	0.00018	0.0115	CcSEcCtD
Pseudoephedrine—Chest pain—Bleomycin—melanoma	0.000179	0.0114	CcSEcCtD
Pseudoephedrine—Rash—Vemurafenib—melanoma	0.000179	0.0114	CcSEcCtD
Pseudoephedrine—Dermatitis—Vemurafenib—melanoma	0.000179	0.0114	CcSEcCtD
Pseudoephedrine—Headache—Vemurafenib—melanoma	0.000178	0.0113	CcSEcCtD
Pseudoephedrine—Confusional state—Bleomycin—melanoma	0.000173	0.011	CcSEcCtD
Pseudoephedrine—Tremor—Carmustine—melanoma	0.000172	0.011	CcSEcCtD
Pseudoephedrine—Agitation—Carmustine—melanoma	0.000169	0.0108	CcSEcCtD
Pseudoephedrine—Nausea—Vemurafenib—melanoma	0.000168	0.0107	CcSEcCtD
Pseudoephedrine—Tremor—Temozolomide—melanoma	0.000166	0.0106	CcSEcCtD
Pseudoephedrine—Angina pectoris—Docetaxel—melanoma	0.000165	0.0105	CcSEcCtD
Pseudoephedrine—Anorexia—Bleomycin—melanoma	0.000164	0.0104	CcSEcCtD
Pseudoephedrine—Agitation—Temozolomide—melanoma	0.000163	0.0104	CcSEcCtD
Pseudoephedrine—Vertigo—Temozolomide—melanoma	0.00016	0.0102	CcSEcCtD
Pseudoephedrine—Hypertension—Carmustine—melanoma	0.000159	0.0101	CcSEcCtD
Pseudoephedrine—Palpitations—Temozolomide—melanoma	0.000157	0.01	CcSEcCtD
Pseudoephedrine—Chest pain—Carmustine—melanoma	0.000156	0.00997	CcSEcCtD
Pseudoephedrine—Anxiety—Carmustine—melanoma	0.000156	0.00993	CcSEcCtD
Pseudoephedrine—Hypertension—Temozolomide—melanoma	0.000153	0.00977	CcSEcCtD
Pseudoephedrine—Dyspnoea—Bleomycin—melanoma	0.000153	0.00976	CcSEcCtD
Pseudoephedrine—Anorexia—Dactinomycin—melanoma	0.000153	0.00973	CcSEcCtD
Pseudoephedrine—Confusional state—Carmustine—melanoma	0.000151	0.00963	CcSEcCtD
Pseudoephedrine—Anxiety—Temozolomide—melanoma	0.000151	0.0096	CcSEcCtD
Pseudoephedrine—Decreased appetite—Bleomycin—melanoma	0.000149	0.00951	CcSEcCtD
Pseudoephedrine—Pain—Bleomycin—melanoma	0.000147	0.00936	CcSEcCtD
Pseudoephedrine—Tachycardia—Carmustine—melanoma	0.000146	0.00932	CcSEcCtD
Pseudoephedrine—Confusional state—Temozolomide—melanoma	0.000146	0.00931	CcSEcCtD
Pseudoephedrine—Anorexia—Carmustine—melanoma	0.000143	0.00911	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Bleomycin—melanoma	0.000142	0.00902	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Temozolomide—melanoma	0.00014	0.00892	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dactinomycin—melanoma	0.000139	0.00887	CcSEcCtD
Pseudoephedrine—Anorexia—Temozolomide—melanoma	0.000138	0.0088	CcSEcCtD
Pseudoephedrine—Pain—Dactinomycin—melanoma	0.000137	0.00873	CcSEcCtD
Pseudoephedrine—Body temperature increased—Bleomycin—melanoma	0.000136	0.00865	CcSEcCtD
Pseudoephedrine—Insomnia—Carmustine—melanoma	0.000136	0.00864	CcSEcCtD
Pseudoephedrine—Dyspnoea—Carmustine—melanoma	0.000134	0.00852	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dactinomycin—melanoma	0.000132	0.00841	CcSEcCtD
Pseudoephedrine—Insomnia—Temozolomide—melanoma	0.000131	0.00835	CcSEcCtD
Pseudoephedrine—Decreased appetite—Carmustine—melanoma	0.00013	0.0083	CcSEcCtD
Pseudoephedrine—Dyspnoea—Temozolomide—melanoma	0.000129	0.00823	CcSEcCtD
Pseudoephedrine—Pain—Carmustine—melanoma	0.000128	0.00817	CcSEcCtD
Pseudoephedrine—Dyspepsia—Temozolomide—melanoma	0.000128	0.00813	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dactinomycin—melanoma	0.000127	0.00807	CcSEcCtD
Pseudoephedrine—Decreased appetite—Temozolomide—melanoma	0.000126	0.00803	CcSEcCtD
Pseudoephedrine—Pain—Temozolomide—melanoma	0.000124	0.00789	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Carmustine—melanoma	0.000124	0.00787	CcSEcCtD
Pseudoephedrine—Asthenia—Bleomycin—melanoma	0.000123	0.00785	CcSEcCtD
Pseudoephedrine—Arrhythmia—Docetaxel—melanoma	0.000121	0.00772	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Temozolomide—melanoma	0.000119	0.00761	CcSEcCtD
Pseudoephedrine—Body temperature increased—Carmustine—melanoma	0.000119	0.00755	CcSEcCtD
Pseudoephedrine—Asthenia—Dactinomycin—melanoma	0.000115	0.00732	CcSEcCtD
Pseudoephedrine—Body temperature increased—Temozolomide—melanoma	0.000115	0.0073	CcSEcCtD
Pseudoephedrine—Muscle spasms—Docetaxel—melanoma	0.000114	0.00723	CcSEcCtD
Pseudoephedrine—Vomiting—Bleomycin—melanoma	0.000109	0.00696	CcSEcCtD
Pseudoephedrine—Rash—Bleomycin—melanoma	0.000108	0.0069	CcSEcCtD
Pseudoephedrine—Dermatitis—Bleomycin—melanoma	0.000108	0.00689	CcSEcCtD
Pseudoephedrine—Asthenia—Carmustine—melanoma	0.000108	0.00685	CcSEcCtD
Pseudoephedrine—Palpitations—Docetaxel—melanoma	0.000104	0.00665	CcSEcCtD
Pseudoephedrine—Asthenia—Temozolomide—melanoma	0.000104	0.00662	CcSEcCtD
Pseudoephedrine—Nausea—Bleomycin—melanoma	0.000102	0.0065	CcSEcCtD
Pseudoephedrine—Hypertension—Docetaxel—melanoma	0.000102	0.00649	CcSEcCtD
Pseudoephedrine—Vomiting—Dactinomycin—melanoma	0.000102	0.00649	CcSEcCtD
Pseudoephedrine—Rash—Dactinomycin—melanoma	0.000101	0.00644	CcSEcCtD
Pseudoephedrine—Chest pain—Docetaxel—melanoma	0.000101	0.0064	CcSEcCtD
Pseudoephedrine—Dizziness—Carmustine—melanoma	9.91e-05	0.00632	CcSEcCtD
Pseudoephedrine—Confusional state—Docetaxel—melanoma	9.72e-05	0.00619	CcSEcCtD
Pseudoephedrine—Dizziness—Temozolomide—melanoma	9.58e-05	0.0061	CcSEcCtD
Pseudoephedrine—Vomiting—Carmustine—melanoma	9.53e-05	0.00607	CcSEcCtD
Pseudoephedrine—Nausea—Dactinomycin—melanoma	9.52e-05	0.00606	CcSEcCtD
Pseudoephedrine—Rash—Carmustine—melanoma	9.45e-05	0.00602	CcSEcCtD
Pseudoephedrine—Dermatitis—Carmustine—melanoma	9.44e-05	0.00602	CcSEcCtD
Pseudoephedrine—Tachycardia—Docetaxel—melanoma	9.4e-05	0.00599	CcSEcCtD
Pseudoephedrine—Headache—Carmustine—melanoma	9.39e-05	0.00598	CcSEcCtD
Pseudoephedrine—Vomiting—Temozolomide—melanoma	9.21e-05	0.00587	CcSEcCtD
Pseudoephedrine—Anorexia—Docetaxel—melanoma	9.18e-05	0.00585	CcSEcCtD
Pseudoephedrine—Rash—Temozolomide—melanoma	9.14e-05	0.00582	CcSEcCtD
Pseudoephedrine—Dermatitis—Temozolomide—melanoma	9.13e-05	0.00582	CcSEcCtD
Pseudoephedrine—Headache—Temozolomide—melanoma	9.08e-05	0.00578	CcSEcCtD
Pseudoephedrine—Nausea—Carmustine—melanoma	8.91e-05	0.00567	CcSEcCtD
Pseudoephedrine—Insomnia—Docetaxel—melanoma	8.71e-05	0.00555	CcSEcCtD
Pseudoephedrine—Nausea—Temozolomide—melanoma	8.61e-05	0.00548	CcSEcCtD
Pseudoephedrine—Dyspnoea—Docetaxel—melanoma	8.59e-05	0.00547	CcSEcCtD
Pseudoephedrine—Dyspepsia—Docetaxel—melanoma	8.48e-05	0.0054	CcSEcCtD
Pseudoephedrine—Decreased appetite—Docetaxel—melanoma	8.38e-05	0.00534	CcSEcCtD
Pseudoephedrine—Pain—Docetaxel—melanoma	8.24e-05	0.00525	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Docetaxel—melanoma	7.94e-05	0.00506	CcSEcCtD
Pseudoephedrine—Body temperature increased—Docetaxel—melanoma	7.62e-05	0.00485	CcSEcCtD
Pseudoephedrine—Asthenia—Docetaxel—melanoma	6.91e-05	0.0044	CcSEcCtD
Pseudoephedrine—Dizziness—Docetaxel—melanoma	6.37e-05	0.00406	CcSEcCtD
Pseudoephedrine—Vomiting—Docetaxel—melanoma	6.13e-05	0.0039	CcSEcCtD
Pseudoephedrine—Rash—Docetaxel—melanoma	6.08e-05	0.00387	CcSEcCtD
Pseudoephedrine—Dermatitis—Docetaxel—melanoma	6.07e-05	0.00387	CcSEcCtD
Pseudoephedrine—Headache—Docetaxel—melanoma	6.04e-05	0.00385	CcSEcCtD
Pseudoephedrine—Nausea—Docetaxel—melanoma	5.72e-05	0.00365	CcSEcCtD
Pseudoephedrine—CYP2D6—Metabolism—CD44—melanoma	3.53e-06	1.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EDN1—melanoma	3.51e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NOTCH1—melanoma	3.51e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FN1—melanoma	3.51e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTGS2—melanoma	3.5e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SPP1—melanoma	3.47e-06	1.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAP2K2—melanoma	3.46e-06	1.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCL8—melanoma	3.46e-06	1.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TP53—melanoma	3.44e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CD80—melanoma	3.44e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CSF2—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGF1—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NOTCH1—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CG—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APC—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KIT—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—NRAS—melanoma	3.43e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EGF—melanoma	3.39e-06	1.54e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP1B1—melanoma	3.39e-06	1.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—IL2—melanoma	3.38e-06	1.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CD80—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—E2F1—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APC—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CG—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KIT—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—NRAS—melanoma	3.36e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CB—melanoma	3.34e-06	1.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PDGFRA—melanoma	3.33e-06	1.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EGF—melanoma	3.32e-06	1.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2—melanoma	3.31e-06	1.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TERT—melanoma	3.29e-06	1.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ITGB3—melanoma	3.29e-06	1.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PRKCA—melanoma	3.29e-06	1.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—HRAS—melanoma	3.29e-06	1.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK3—melanoma	3.28e-06	1.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RAC1—melanoma	3.28e-06	1.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SPP1—melanoma	3.23e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—BRAF—melanoma	3.22e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAP2K2—melanoma	3.22e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCL8—melanoma	3.21e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK3—melanoma	3.21e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—BRAF—melanoma	3.15e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HIF1A—melanoma	3.15e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF1—melanoma	3.14e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK1—melanoma	3.13e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—EGFR—melanoma	3.12e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CG—melanoma	3.08e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF1—melanoma	3.07e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2—melanoma	3.07e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TERT—melanoma	3.06e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK1—melanoma	3.06e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—EGFR—melanoma	3.06e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTEN—melanoma	3.06e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RAC1—melanoma	3.05e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAP2K1—melanoma	3.04e-06	1.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CD—melanoma	3.02e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KDR—melanoma	3.01e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	2.99e-06	1.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PPARG—melanoma	2.98e-06	1.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAP2K1—melanoma	2.97e-06	1.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—melanoma	2.95e-06	1.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CD—melanoma	2.95e-06	1.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HIF1A—melanoma	2.93e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	2.92e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—AKT1—melanoma	2.9e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FN1—melanoma	2.9e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—melanoma	2.89e-06	1.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FGF2—melanoma	2.89e-06	1.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NOTCH1—melanoma	2.84e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FGF2—melanoma	2.82e-06	1.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KDR—melanoma	2.8e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ABCB1—melanoma	2.79e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CD80—melanoma	2.78e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CG—melanoma	2.78e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APC—melanoma	2.78e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KIT—melanoma	2.78e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—NRAS—melanoma	2.78e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EGF—melanoma	2.74e-06	1.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PIK3CA—melanoma	2.71e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CD—melanoma	2.71e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MDM2—melanoma	2.7e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FN1—melanoma	2.69e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ALB—melanoma	2.68e-06	1.22e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ERBB2—melanoma	2.66e-06	1.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK3—melanoma	2.66e-06	1.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PIK3CA—melanoma	2.65e-06	1.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MDM2—melanoma	2.64e-06	1.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	2.64e-06	1.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CB—melanoma	2.63e-06	1.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BRAF—melanoma	2.61e-06	1.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ERBB2—melanoma	2.61e-06	1.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CD80—melanoma	2.58e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	2.58e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APC—melanoma	2.58e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KIT—melanoma	2.58e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—NRAS—melanoma	2.58e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CB—melanoma	2.57e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PRKCA—melanoma	2.57e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EGF—melanoma	2.55e-06	1.16e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ERCC2—melanoma	2.54e-06	1.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF1—melanoma	2.54e-06	1.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK1—melanoma	2.53e-06	1.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—EGFR—melanoma	2.53e-06	1.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCL8—melanoma	2.53e-06	1.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—HRAS—melanoma	2.51e-06	1.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL8—melanoma	2.47e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	2.47e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1B—melanoma	2.47e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAP2K1—melanoma	2.46e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—HRAS—melanoma	2.45e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—AKT1—melanoma	2.44e-06	1.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CD—melanoma	2.44e-06	1.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BRAF—melanoma	2.42e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CASP3—melanoma	2.42e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	2.42e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2—melanoma	2.41e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1B—melanoma	2.41e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—melanoma	2.4e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—melanoma	2.39e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—AKT1—melanoma	2.39e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CASP3—melanoma	2.36e-06	1.08e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CB—melanoma	2.36e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2—melanoma	2.36e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF1—melanoma	2.36e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCND1—melanoma	2.35e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	2.35e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—melanoma	2.35e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—EGFR—melanoma	2.35e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS2—melanoma	2.34e-06	1.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGF2—melanoma	2.34e-06	1.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CTNNB1—melanoma	2.33e-06	1.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCND1—melanoma	2.3e-06	1.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP9—melanoma	2.28e-06	1.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	2.28e-06	1.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CTNNB1—melanoma	2.28e-06	1.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1A—melanoma	2.28e-06	1.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTEN—melanoma	2.27e-06	1.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	2.27e-06	1.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NFKB1—melanoma	2.26e-06	1.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	2.25e-06	1.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP9—melanoma	2.23e-06	1.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1A—melanoma	2.23e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTEN—melanoma	2.22e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—melanoma	2.22e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—AKT1—melanoma	2.22e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NFKB1—melanoma	2.21e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	2.19e-06	9.98e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MDM2—melanoma	2.19e-06	9.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGF2—melanoma	2.17e-06	9.87e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—AKT1—melanoma	2.17e-06	9.85e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CA—melanoma	2.16e-06	9.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ERBB2—melanoma	2.15e-06	9.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CB—melanoma	2.13e-06	9.67e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—melanoma	2.05e-06	9.33e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL8—melanoma	2.04e-06	9.29e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTEN—melanoma	2.04e-06	9.28e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	2.04e-06	9.27e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STAT3—melanoma	2.03e-06	9.24e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MDM2—melanoma	2.03e-06	9.23e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—HRAS—melanoma	2.03e-06	9.23e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NRAS—melanoma	2.03e-06	9.21e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CG—melanoma	2.01e-06	9.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—melanoma	2.01e-06	9.12e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ERBB2—melanoma	2e-06	9.1e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1B—melanoma	2e-06	9.07e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STAT3—melanoma	1.99e-06	9.03e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NRAS—melanoma	1.98e-06	9.01e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	1.98e-06	8.98e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	1.97e-06	8.98e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CASP3—melanoma	1.96e-06	8.89e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2—melanoma	1.95e-06	8.88e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—melanoma	1.94e-06	8.84e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK3—melanoma	1.94e-06	8.82e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PPARG—melanoma	1.94e-06	8.82e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCND1—melanoma	1.9e-06	8.66e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL8—melanoma	1.9e-06	8.63e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK3—melanoma	1.9e-06	8.63e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MYC—melanoma	1.89e-06	8.58e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—HRAS—melanoma	1.89e-06	8.58e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	1.89e-06	8.57e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	1.85e-06	8.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP9—melanoma	1.85e-06	8.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK1—melanoma	1.85e-06	8.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MYC—melanoma	1.85e-06	8.39e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EGFR—melanoma	1.85e-06	8.39e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	1.84e-06	8.37e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTEN—melanoma	1.84e-06	8.36e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	1.83e-06	8.34e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NFKB1—melanoma	1.83e-06	8.31e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CASP3—melanoma	1.82e-06	8.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2—melanoma	1.81e-06	8.25e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK1—melanoma	1.81e-06	8.21e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EGFR—melanoma	1.81e-06	8.21e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—melanoma	1.81e-06	8.21e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—AKT1—melanoma	1.79e-06	8.15e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCND1—melanoma	1.77e-06	8.04e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CD—melanoma	1.77e-06	8.03e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—AKT1—melanoma	1.76e-06	8.01e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	1.75e-06	7.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—melanoma	1.74e-06	7.93e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALB—melanoma	1.74e-06	7.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP9—melanoma	1.72e-06	7.81e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	1.71e-06	7.78e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTEN—melanoma	1.71e-06	7.76e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—melanoma	1.71e-06	7.76e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NFKB1—melanoma	1.7e-06	7.73e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AKT1—melanoma	1.67e-06	7.57e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—melanoma	1.66e-06	7.55e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STAT3—melanoma	1.64e-06	7.47e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NRAS—melanoma	1.64e-06	7.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CA—melanoma	1.6e-06	7.28e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK3—melanoma	1.57e-06	7.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CA—melanoma	1.57e-06	7.13e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—melanoma	1.55e-06	7.05e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—melanoma	1.54e-06	7.01e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CB—melanoma	1.54e-06	7e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MYC—melanoma	1.53e-06	6.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STAT3—melanoma	1.53e-06	6.94e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS2—melanoma	1.53e-06	6.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NRAS—melanoma	1.52e-06	6.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—melanoma	1.52e-06	6.89e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK1—melanoma	1.49e-06	6.79e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EGFR—melanoma	1.49e-06	6.79e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HRAS—melanoma	1.48e-06	6.74e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK3—melanoma	1.46e-06	6.63e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HRAS—melanoma	1.45e-06	6.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CA—melanoma	1.44e-06	6.55e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MYC—melanoma	1.42e-06	6.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—melanoma	1.42e-06	6.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—melanoma	1.41e-06	6.42e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK1—melanoma	1.39e-06	6.31e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—melanoma	1.39e-06	6.31e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EGFR—melanoma	1.39e-06	6.31e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTEN—melanoma	1.33e-06	6.05e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—melanoma	1.31e-06	5.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKT1—melanoma	1.31e-06	5.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	1.3e-06	5.89e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKT1—melanoma	1.28e-06	5.82e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—melanoma	1.25e-06	5.7e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	1.2e-06	5.48e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HRAS—melanoma	1.2e-06	5.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKT1—melanoma	1.18e-06	5.35e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—melanoma	1.17e-06	5.3e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—melanoma	1.15e-06	5.22e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HRAS—melanoma	1.11e-06	5.07e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—melanoma	1.07e-06	4.85e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKT1—melanoma	1.06e-06	4.82e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKT1—melanoma	9.84e-07	4.47e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CA—melanoma	9.39e-07	4.27e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKT1—melanoma	7.67e-07	3.49e-06	CbGpPWpGaD
